Dr. Steven G. Lin, MD

Dr. Lin practices at Pacific Eye Institute, a Medical Group, Inc. in Palm Springs, California.

Dr. Lin's NPI, 1457343568, was assigned on August 16, 2005. Dr. Lin graduated from SUNY Downstate Health Sciences University in 1992. Dr. Lin's California license number on file is G84610.

Dr. Lin's primary practice is Pacific Eye Institute, a Medical Group, Inc., at 340 S Farrell Dr, Palm Springs, CA 92262 in Riverside County. The practice phone is (909) 982-8846.

Dr. Lin's primary practice is Pacific Eye Institute, a Medical Group, Inc. in Palm Springs, California. Dr. Lin is also affiliated with Desert Regional Medical Center. Dmand AI also links Dr. Lin to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 3 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Lin is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Lin's licenses on file in 2 states: California and Louisiana.

Dmand AI lists age-related macular degeneration, cataract surgery with lens implant, eye infection or inflammation, glaucoma, hypertensive retinopathy, inflammation of iris, laser destruction of retinal or choroid lesions and retinal detachment among the conditions Dr. Lin treats.

CMS data shows 39,724 Medicare services from Dr. Lin across 12 procedure codes in 2024, for 968 Medicare patients. Medicare paid $2,293,561 for them. Every service was in an office.

CMS counts 968 Medicare patients who saw Dr. Lin in 2024. The largest group is 75 to 84, with 424 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 77, with 50% women.

In 2024, Dr. Lin wrote 1,163 Medicare Part D claims for 243 patients. 67% of them were for generic drugs. CMS names the drug for 1,102 of them, across 17 drugs with 11 or more claims each, at $94,255 in total drug cost. In 2023, CMS named 980 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Lin, published from 2006 to 2022. 2020 was the busiest year, with 2. The most frequent topics are Fluorescein Angiography, Tomography, Optical Coherence and Visual Acuity. Dr. Lin has published most often in Retina. Dr. Lin's most frequent co-authors are Clement K. Chan, MD, Maziar Lalezary, MD and Prema Abraham, MD.

Dmand AI links Dr. Lin to 2 clinical trials. Conditions studied include Wet Macular Degeneration and Glycogen Storage Disease Type II. Southern California Desert Retina Consultants, MC sponsors the most, 2.

CMS Open Payments shows 107 general payments to Dr. Lin from 17 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 67% of the total. Genentech, Inc. paid the most, $1,138.

Dmand AI lists 2 awards for Dr. Lin, most recently Palm Springs Life Magazine in 2014.

Dr. Lin graduated from SUNY Downstate Health Sciences University in 1992. Dr. Lin is a member of AAO.

Dr. Lin is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.